| Q44104686 | A puzzling case of portal hypertension in a patient with human immunodeficiency and hepatitis C virus co-infection |
| Q46433832 | A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand |
| Q45002669 | ANRS HC 02 RIBAVIC: summary and recommandations |
| Q33802414 | Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study |
| Q28070280 | Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections |
| Q36063045 | Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview |
| Q41522665 | Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases |
| Q37272320 | Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography |
| Q35980035 | Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. |
| Q41466494 | Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial |
| Q42205158 | Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France |
| Q37952808 | CCL5: a double-edged sword in host defense against the hepatitis C virus |
| Q46370317 | Changing trends in hepatitis C-related mortality in the United States, 1995-2004. |
| Q40451354 | Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis. |
| Q37625493 | Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems |
| Q36830375 | Clinical implications of HIV and hepatitis B co-infection in Asia and Africa |
| Q36542793 | Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin |
| Q27488883 | Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes |
| Q36566930 | Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects |
| Q34052838 | Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals |
| Q36461601 | Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection |
| Q35050640 | Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial |
| Q42272013 | Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration |
| Q64135831 | Correlates of same-sex behavior disclosure to health care providers among Black MSM in the United States: implications for HIV prevention |
| Q46132353 | Darunavir in HIV/HVC/HVB coinfection |
| Q37191549 | Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. |
| Q35088330 | Drinking trajectories among HIV-infected men who have sex with men: a cohort study of United States veterans |
| Q35793581 | Drug trafficking routes and hepatitis B in injection drug users, Manipur, India |
| Q36787476 | Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation |
| Q35772764 | Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia |
| Q92986846 | Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study) |
| Q34191840 | Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France) |
| Q27486399 | Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals |
| Q35980818 | Epidemiological implications of HIV-hepatitis C co-infection in South and Southeast Asia |
| Q33870620 | Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome |
| Q36034450 | Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV. |
| Q39018310 | Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. |
| Q42977642 | Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient |
| Q33999114 | Global challenges in liver disease |
| Q35685474 | HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons |
| Q38651617 | HBV infection in untreated HIV-infected adults in Maputo, Mozambique. |
| Q44300005 | HIV and hepatitis C virus coinfection |
| Q34758927 | HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. |
| Q35184027 | HIV-1 Nef is transferred from expressing T cells to hepatocytic cells through conduits and enhances HCV replication |
| Q34844389 | HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies |
| Q37124502 | Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort |
| Q54230566 | Hepatitis B Vaccination Induced TNF-α- and IL-2-Producing T Cell Responses in HIV- Healthy Individuals Higher than in HIV+ Individuals Who Received the Same Vaccination Regimen. |
| Q34831090 | Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals |
| Q35780728 | Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda |
| Q26822862 | Hepatitis B and human immunodeficiency virus co-infection |
| Q36750298 | Hepatitis C and HIV. |
| Q42225407 | Hepatitis C treatment eligibility among HIV-hepatitis C virus coinfected patients in Oregon: a population-based sample |
| Q36668229 | Hepatocellular cancer in HIV-infected individuals: tomorrow's problem? |
| Q30379450 | High Prevalence of Liver Fibrosis in Patients with Human Immunodeficiency Virus Monoinfection and Human Immunodeficiency Virus Hepatitis-B Co-infection as Assessed by Shear Wave Elastography: Study at a Teaching Hospital in Kenya |
| Q35125231 | High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda |
| Q64067126 | Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody |
| Q33430799 | Impact of Obliterative Portal Venopathy Associated With Human Immunodeficiency Virus |
| Q36496736 | Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy |
| Q33811374 | Incidence of hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study |
| Q37860640 | Increasing burden of liver disease in patients with HIV infection |
| Q34367370 | Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients |
| Q37374339 | Interventions to reduce alcohol use among HIV-infected individuals: a review and critique of the literature |
| Q33410098 | Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts |
| Q90727838 | Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? |
| Q37328254 | Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role? |
| Q37874569 | Liver transplantation in human immunodeficiency virus-positive patients |
| Q41592007 | Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey |
| Q45407116 | Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). |
| Q36715589 | Low-level HIV infection of hepatocytes. |
| Q27490545 | MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease |
| Q43823859 | Management of HCV-HIV and HBV-HIV coinfected patients |
| Q30234831 | Management of hepatitis C virus infection in the Asia-Pacific region: an update |
| Q61865985 | Markov modelling of HIV infection evolution in the HAART era |
| Q33585762 | Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression |
| Q35800310 | National Trend and Characteristics of Acute Hepatitis C among HIV-Infected Individuals: A Matched Case-Control Study-Taiwan, 2001-2014. |
| Q35653358 | New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy |
| Q36712169 | New paradigms in the management of hepatitis C virus co-infections |
| Q35834104 | Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy |
| Q34157953 | Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects |
| Q44156088 | Nutrition issues in the HIV-infected injection drug user: findings from the nutrition for healthy living cohort |
| Q63284676 | Peut-on améliorer la couverture vaccinale contre l’hépatite B chez les malades infectés par le VIH ? |
| Q37628545 | Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection |
| Q40237305 | Phosphatidylethanol (PEth) as a Biomarker of Alcohol Consumption in HIV-Infected Young Russian Women: Comparison to Self-Report Assessments of Alcohol Use. |
| Q47553396 | Point-of-Care Urine Ethyl Glucuronide Testing to Detect Alcohol Use Among HIV-Hepatitis B Virus Coinfected Adults in Zambia |
| Q45097162 | Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine |
| Q36539302 | Porphyromonas gingivalis induces CCR5-dependent transfer of infectious HIV-1 from oral keratinocytes to permissive cells. |
| Q36131256 | Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients |
| Q45400034 | Prevalence of hepatitis B virus infection in Japanese patients with HIV. |
| Q27489610 | Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S |
| Q36285986 | Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies |
| Q36619816 | Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV |
| Q37003753 | Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status |
| Q40398857 | Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents |
| Q42983977 | Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis |
| Q38870021 | Right Atrial Mass in a Patient With HIV and Hepatitis B: A Case Report |
| Q84465983 | Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese |
| Q26775931 | Role of liver transplantation in human immunodeficiency virus positive patients |
| Q43179932 | Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection |
| Q48094944 | Self-reported changes in alcohol use behavior among people living with HIV in China after receiving HIV positive diagnosis. |
| Q38130927 | Seroprevalence of hepatitis B in a cohort of HIV-infected children and adults in Swaziland |
| Q58715600 | Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection |
| Q38219424 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. |
| Q59357554 | Solid Organ Transplantation for HIV-Infected Individuals |
| Q36672577 | Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection |
| Q34026982 | Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era. |
| Q34474434 | Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C) |
| Q40678434 | The Framingham function overestimates the risk of ischemic heart disease in HIV-infected patients from Barcelona. |
| Q34218503 | The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. |
| Q41623032 | The prevalence of hepatitis B virus infection markers and socio-demographic risk factors in HIV-infected patients in Southern Brazil. |
| Q46528075 | The risk of hepatocellular carcinoma in patients with previous malignancy |
| Q42126435 | The role of discrimination in alcohol-related problems in samples of heavy drinking HIV-negative and positive men who have sex with men (MSM) |
| Q37123546 | Trends in the incidence of primary liver cancer in Central Uganda, 1960-1980 and 1991-2005. |
| Q34086980 | Viral hepatitis in HIV infection |